NIH funding opportunities

14 Nov 2023 (#35)

Confirm your intent to apply ASAP, but not later than 60 days before the submission date.

See all Important Notices, Parent Announcements and Notice of Special Interest below

Plan your application. Before starting your application attend

1) *Generic Grant Writing Workshop and then the*

2) NIH Grant Writing Workshop

To prepare an application can take 4-18 months.

From submission to receiving a Notice of Award can take 10 months

Important Notices

CRDF Global: The U.S. National Institutes of Health (NIH) through the National Institute of Allergy and Infectious Diseases (NIAID) and the South African Medical Research Council (SAMRC), invite researchers to submit full proposals for the **Regional Prospective Observational Research in Tuberculosis in the Republic of South Africa: RePORT South Africa Phase III**. This initiative will provide a maximum of three (3) years of funding to support one (1) award to advance fundamental and clinical research in areas of TB and TB/HIV in South Africa. Full proposals must be submitted to CRDF Global's point of contact, Ms. Aisha Eiger, aeiger@crdfglobal.org no later than Friday, December 1, 2023, (4:59 PM) U.S. Eastern Standard Time (EST) i.e. 11:59 PM South African Standard Time (SAST). Proposals will undergo a round of joint peer evaluation by the U.S. and South African technical reviewers.

NOT-TW-23-008 Notice of Participation of FIC in RFA-HD-24-009, "Prevention and Treatment through a Comprehensive Care Continuum for HIV-affected Adolescents in Resource Constrained Settings Implementation Science Network (PATC³H-IN) 2" Scientific/Research Contact Dr Geetha P. Bansal: geetha.bansal@nih.gov.

Parent Announcements

NOT-OD-23-105 Notice to Extend Parent R01/R03/R21 Parent Notices of Funding Opportunities. Current Key Dates *Expiration Date: May 8, 2023.* **Modified *Expiration Date: May 8, 2024***

Parent Announcements (PA) for unsolicited are broad funding opportunity announcements allowing applicants to submit investigator-initiated applications. They are open for up to 3 years and use standard due dates.

- **PA-20-185** NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
- **PA-20-184** Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)
- **PA-20-183** Research Project Grant (Parent R01 Clinical Trial Required)
- **PA-20-200** NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)
- **PA-20-195** NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
- **PA-20-194** NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)

- PA-20-196 NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)

Notice of Special Interest

NOT-HD-23-021 **The Road to Prevention of Stillbirth.** This NOSI aims to support transdisciplinary research to elucidate the genotypic, phenotypic, and environmental underpinnings of stillbirth and to identify potential targets for intervention and prevention. This notice applies to due dates on or after October 5, 2023, and subsequent receipt dates through November 17, 2026.

Notice of Funding Opportunity (NOFO)

1. PAR-24-037 **HIV Vaccine Research and Design (HIVRAD) Program (P01 Clinical Trial Not Allowed).** The purpose of this Notice of Funding Opportunity (NOFO) is to support multi-component, multi-disciplinary projects that address scientific questions relevant to AIDS prophylactic vaccine discovery research. Extensive evaluation of vaccine concepts in non-human primate models may be included.

Due dates: March 13, 2024; March 13, 2025; March 13, 2026. Due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Letter of Intent:** 30 days prior to the application due date.

Budget: NIH intends to fund an estimate of 1-2 awards, corresponding to a total of $5.0M, for fiscal year 2025. Future year amounts will depend on annual appropriations. Application budgets are not expected to exceed $2,500,000 in direct costs per year and should reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

2. RFA-DA-24-034 **Mechanistic Research on Neuromodulation for Substance Use Disorders Treatment (R61/R33 Basic Experimental Studies with Humans Required).** The purpose of this notice of funding opportunity (NOFO) is to encourage clinical research that will identify and validate 1) Novel targets for non-invasive brain stimulation (NIBS) to treat substance use disorders (SUD) and 2) Substance use disorder (SUD)-relevant neurobiological, cognitive, and behavioral responses to NIBS that may precede clinical outcomes like reduced craving or substance use. Applications are expected to be exploratory and developmental in nature. As such, these studies may involve considerable risk of failure but may lead to a breakthrough in a particular area that could have a major impact on SUD research involving NIBS. This NOFO uses a R61/R33 Phased Innovation award activity code to support applications that propose Basic Experimental Studies Involving Humans (BESH) that meet both the definition of basic research and the NIH definition of a clinical trial. Types of studies that should submit under this NOFO include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn. Applicants are strongly encouraged to read the NOFO instructions carefully and view the available PEDP guidance material.

Due dates: January 16, 2024 through to August 14, 2026. Due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Letter of Intent:** 30 days prior to the application due date.

Budget: NIDA intends to commit $1.5M in FYs 2024, 2025, and 2026 to fund up to six awards in response to this NOFO and the companion NOFOs RFA-DA-24-031, RFA-DA-24-032, and RFA-DA-24-033. For the R61 planning phase, the combined budget for direct costs for up to two years may not exceed $600,000. For the R33 phase, budgets are not limited, but need to reflect the actual needs of the proposed project. The maximum period of the combined R61 and R33 phases is 5 years, with up to 2 years for the R61 phase and up to 3 years for the R33 phase. The scope of the proposed project should determine the requested project period.

3. RFA-DA-25-011 **Exploratory studies to investigate mechanisms of HIV infection, replication, latency, and/or pathogenesis in the context of substance use disorders (R01 Clinical Trial Not Allowed).** This notice of funding opportunity (NOFO) will support high risk high impact studies that 1) develop or apply novel tools or technologies or 2) test novel hypotheses to investigate mechanistic questions in HIV infection, replication, latency, and/or pathogenesis (including neuroHIV) in the context of Substance Use Disorders (SUDs). This initiative focuses on exploration and characterization of signaling pathways that are involved in CNS HIV establishment and expansion. The NOFO aims to promote milestone-driven research to investigate the underlying molecular mechanisms by which HIV infection is initiated, established, and maintained in the CNS and to determine how addictive substances modulate HIV infection, latency and the size and persistence of CNS HIV reservoirs.

Due dates: August 14, 2024; August 14, 2025. Due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Letter of Intent:** 30 days prior to the application due date.

Budget: NIDA intends to support up to three awards, corresponding to a total of $2,000,000 in FY 2025. Future year amounts will depend on annual appropriations. Applications may not request more than $700K direct costs for any single year. The maximum project period is 5 years.

4. RFA-DA-25-059 **Ending the Epidemic: New Models of Integrated HIV/AIDS, Addiction, and Primary Care Services (R34 Clinical Trial Optional).** The purpose of this notice of funding opportunity (NOFO) is to support the development and testing of enhanced models of care that optimally integrate HIV, Hepatitis B and C, addiction, and primary care services. The National Institute on Drug Abuse (NIDA) is interested in research that addresses gaps related to the delivery of comprehensive, integrated health services to include the full continuum of HIV/AIDS services, addiction prevention and treatment services, and primary care services, with a goal of improving the coordination of care, and improving health outcomes related to HIV, Hepatitis (optional), and substance use disorder (SUD) in the US.

Due dates: August 20, 2024, March 19, 2025. Due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Letter of Intent:** 30 days prior to the application due date.

Budget: NIDA expects to fund a total of $2M in new awards in FY25 across both the R01 and R34 mechanisms. Future year amounts will depend on annual appropriations. Direct costs are limited to $450,000 over the 3-year R34 project period, with no more than $225,000 in direct costs allowed in any single year. The scope of the proposed project should determine the project period. The maximum project period is 3 years.

5. RFA-FD-24-001 **Data Standards for Tobacco Research and Scientific Review Phase 2.** The Center for Tobacco Products (CTP) at the Food and Drug Administration (FDA) invites applications for data standards and terminologies development projects to support high-quality tobacco research, streamline scientific review, and evaluation, and ultimately, improve public health outcomes related to tobacco use. The primary objective is to support open, consensus-based, data standards for use in studies of tobacco products. A secondary objective is to promote and educate federal regulators, tobacco industry, and global organizations on the use of standardized data to facilitate data sharing, integration, and analysis. Projects may focus on solutions to data standards and terminologies development and implementation challenges and/or on specific concepts, domains, or areas where standardization is needed.

Due dates: December 13, 2023, by 11:59 **PM Eastern Time.** Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Letter of Intent:** 30 days prior to the application due date.

Budget: FDA /Center for Tobacco Products intends to make 2 awards not to exceed $250,000 in total costs (direct plus indirect) per award. The scope of the proposed project should determine the project period. The maximum project period is two (2) years. Optional additional years of support is possible via submission of a renewal application, contingent upon annual appropriations, availability of funding and satisfactory recipient performance.

6. PAR-24-047 **Revision Applications for Validation of Biomarker Assays Developed Through NIH-Supported Research Grants (R01 Clinical Trial Not Allowed).** Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) encourages revision applications (formerly called "competing revisions") from currently funded NCI R01 research projects. The applicants should propose projects that are expected to accelerate the pace of

translation of NCI-supported methods/assays/technologies (referred to as "assays") to the clinic. Specifically, the focus of applications submitted in response to this NOFO should be on the adaption and clinical validation of molecular/cellular/imaging markers (referred to as "markers" or "biomarkers") for cancer detection, diagnosis, prognosis, monitoring, and prediction of response in treatment, as well as markers for cancer prevention and control. Applications may support the acquisition of well-annotated specimens from NCI-supported or other clinical trials or observational cohorts/consortia for the purpose of clinical validation of the assay. Research projects proposed in response to this NOFO encourage multidisciplinary interaction among scientific investigators, assay developers, clinicians, statisticians, and clinical laboratory staff. Clinical laboratory scientist(s) and statistical experts are highly encouraged to comprise integral parts of the application. This NOFO is not intended to support early-stage development of technology or the conduct of clinical trials, but rather the adaption and validation of assays to the point where they could be integrated into clinical trials as investigational assays/tools/devices.

Due dates: February 20, 2024 through to October 13, 2026 by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Letter of Intent:** 30 days prior to the application due date.

Budget: Application budgets are limited to $150,000 in direct costs in any single year. The parent grant must be active when the application is submitted. There must be a minimum two years of support remaining on the parent award (not to include a no cost extension) at the estimated time of award. If a no-cost extension is needed on the parent grant, it must be in place before the revision application is submitted. The maximum project period is 3 years.

7. RFA-AI-23-057 **Multidisciplinary Research to Accelerate Hepatitis B Cure in Persons Living with HIV and HBV (U19 Clinical Trial Not Allowed).** The purpose of this Notice of Funding Opportunity (NOFO) is to support research to better understand the impact of host and viral heterogeneity on pathogenesis of disease, viral persistence, and immunopathology of Hepatitis B (HBV) and inform cure strategies for HBV in people living with HIV (PLWH). Applicants will establish multidisciplinary teams that span the clinical and basic/translational research arenas and establish an observational cohort to accelerate discovery and increase clinical impact.

Due dates: March 13, 2024. Due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Letter of Intent:** 30 days prior to the application due date.

Budget: NIAID intends to commit $6 million in FY 2025 to fund 1-3 awards. Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years

Faculty of Medicine and Health Sciences **Research & Internationalisation Development & Support (RIDS) & Grants Management Office (GMO)** 009 Kth Floor, Teaching Block, Tygerberg Campus.	**Stellenbosch Campus** **Division for Research Development (DRD)** 2041 Krotoa Building, Ryneveld Street
Enquiries: fmhsgmo@sun.ac.za	**Enquiries:** research@sun.ac.za
Add "*Interest in NIH opportunity*" in the subject line. Add the *notice number* in the text of the email.	